![Atara Bio](https://parsers.vc/logo/9bfd3524-f2e5-471b-850f-0bc78b98954e-4.webp)
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Working at Atara
People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way.
With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Working at Atara
People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way.
Location: United States, California, South San Francisco
Employees: 501-1000
Total raised: $90.5M
Founded date: 2012
Investors 4
Date | Name | Website |
- | Domain Ass... | domainvc.c... |
- | Kleiner Pe... | kleinerper... |
- | EcoR1 Capi... | ecor1cap.c... |
- | DAG Ventur... | dagventure... |
Funding Rounds 2
Date | Series | Amount | Investors |
10.01.2014 | Series B | $52M | - |
17.12.2013 | Series B | $38.5M | - |
Mentions in press and media 22
Date | Title | Description |
23.06.2024 | Pierre Fabre Laboratories Wins Prestigious Galien International Prize for EBVALLO® | Pierre Fabre Laboratories has been honored with the prestigious "Prix Galien International" Prize for their groundbreaking immunotherapy, EBVALLO®. This innovative treatment offers hope to patients with a rare cancer, post-transpl... |
21.06.2024 | Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer | CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic... |
21.06.2024 | Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer | CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic... |
23.02.2024 | Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies | 70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative pr... |
27.01.2022 | Fujifilm expands in US after $100M deal for Atara's manufacturing site and employees | Atara Biotherapeutics has worked on advancing its allogeneic T-cell therapy platform for patients with cancer and autoimmune disease for years, with much of the focus on the ever-tricky task of manufacturing such a the... |
09.04.2021 | John Robinson recruits a small band of Array vets to kickstart discovery at Cogent; Syntimmune co-founder takes charge at Arch Oncology | John Robinson Biotech is a small world — and all the more so in a tight-knit community like Boulder, CO. A serendipitous reunion with Andrew Robbins, a former colleague at Array, was what sparked John Robinson’s jump to his ne... |
01.03.2021 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 1, 2021-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients ... |
04.12.2018 | Atara’s EBV-CTLs show responses in hard-to-treat transplant complication | What makes PTLD especially difficult to treat when it reaches the CNS is that one of the standard PTLD treatments, Roche’s Rituxan (rituximab), is unable to get through the blood-brain barrier, said Atara Chief Medical Officer Dietmar Berge... |
29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
10.01.2014 | Atara Biotherapeutics Raises $52M | Thousand Oaks-based Atara Biotherapeutics announced this morning that it is in a second close of its Series B funding round, bringing its total raised in the funding to $52M. According to Atari Biotherapeutics, the investors in the round in... |
Show more